We are delighted to be named a finalist for the 2024 Communiqué Awards in the Excellence in Communicating and Using Data category for our submission, First Consensus Recommendations for Holistic Care in Hereditary ATTR Amyloidosis.
Through this project for Alnylam Pharmaceuticals, we developed the first published recommendations to recognize the value of the patient community in advocating for the needs of patients with ATTRv amyloidosis, and to call for a major shift in the current approach to its management. These recommendations were published in BMJ Open, a peer-reviewed, open access journal with wide dissemination to a global audience.
The Communiqué Awards “recognize, reward and commend excellence and best practices in medical affairs and healthcare communications.”
For more information about the awards, click here.
The awards take place on July 4 in London.
